A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.

被引：1
|
作者：
Coleman, Robert L.
Concin, Nicole
Herzog, Thomas J.
Woelber, Linn Lena
Mirza, Mansoor Raza
Monk, Bradley J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS5601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5601
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial
    Xu, Q.
    Chen, C.
    Huang, Z.
    Lin, Y.
    Liu, J.
    Li, L.
    Li, Z.
    Pan, J.
    Chen, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S752 - S753
  • [22] Efficacy and safety of sintilimab plus albumin-bound- paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial
    Wang, Yin
    Zhao, Jing
    Liang, Haixi
    Liu, Junxiu
    Huang, Shenjiao
    Zou, Guorong
    Huang, Xin
    Lan, Chunyan
    ECLINICALMEDICINE, 2023, 65
  • [23] Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
    Xu, Qin
    Wang, Junjie
    Sun, Yang
    Lin, Yibin
    Liu, Jing
    Zhuo, Yanhong
    Huang, Zhangzhou
    Huang, Songhua
    Chen, Ying
    Chen, Li
    Ke, Meifang
    Li, Li
    Li, Zirong
    Pan, Junping
    Song, Yanwen
    Liu, Rongqiang
    Chen, Chuanben
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : 1795 - +
  • [24] Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial
    Wu, Xiaohua
    Ji, Jiafu
    Lou, Hanmei
    Li, Yunxia
    Feng, Mei
    Xu, Nong
    Li, Yuzhi
    Wang, Jing
    Huang, Yi
    Lou, Ge
    An, Ruifang
    Li, Changzheng
    Zhou, Qi
    Huang, Xin
    Zhao, Enfeng
    Liu, Tianshu
    Fan, Qingxia
    Li, Guiling
    Li, Baiyong
    Xia, Yu
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S47 - S48
  • [25] Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).
    Vergote, Ignace
    Concin, Nicole
    Mirza, Mansoor Raza
    Andreassen, Camilla Mondrup
    Lorusso, Domenica
    Gennigens, Christine N.
    Banerjee, Susana N.
    O'Cearbhaill, Roisin Eilish
    Campos, Susana
    Nicacio, Leonardo Viana
    Eaton, Lamar
    O'Malley, David M.
    Soumaoro, Ibrahima
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Disitamab vedotin (RC48) for previously treated HER2-expressing metastatic breast cancer with abnormal activation of PAM pathway: Results from a single-arm, prospective phase II clinical trial
    Wu, Y.
    Mo, H.
    Sun, X.
    Peng, X.
    Ma, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S379 - S379
  • [27] Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
    Xu, Qin
    Chen, Chuanben
    Sun, Yang
    Huang, Zhangzhou
    Lin, Yibin
    Liu, Jing
    Li, Li
    Li, Zirong
    Pan, Junping
    Chen, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study
    Xia, Lingfang
    Wang, Jing
    Wang, Chunyan
    Zhang, Qingming
    Zhu, Jianqing
    Rao, Qunxian
    Cheng, Huijun
    Liu, Zheng
    Yin, Yongmei
    Ai, Xiaohong
    Gulina, Kurban
    Zheng, Hong
    Luo, Xiaoyong
    Chang, Baoping
    Li, Li
    Liu, Haiyan
    Li, Yunxia
    Lou, Ge
    Zhou, Qi
    Zhu, Yanling
    Xiao, Zemin
    Tong, Jiandong
    Wang, Ke
    Chen, Jie
    Wang, Xia
    Song, Lijie
    Wei, Zhixia
    Ye, Yijing
    Zhu, Jiman
    Wu, Xiaohua
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (12) : 1861 - 1868
  • [29] Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
    Morris, Van K.
    Salem, Mohamed E.
    Nimeiri, Halla
    Iqbal, Syma
    Singh, Preet
    Ciombor, Kristen
    Polite, Blase
    Deming, Dustin
    Chan, Emily
    Wade, James L.
    Xiao, Lianchun
    Bekaii-Saab, Tanios
    Vence, Luis
    Blando, Jorge
    Mahvash, Armeen
    Foo, Wai Chin
    Ohaji, Chimela
    Pasia, Manolo
    Bland, Gail
    Ohinata, Aki
    Rogers, Jane
    Mehdizadeh, Amir
    Banks, Kimberly
    Lanman, Richard
    Wolff, Robert A.
    Streicher, Howard
    Allison, James
    Sharma, Padmanee
    Eng, Cathy
    LANCET ONCOLOGY, 2017, 18 (04): : 446 - 453
  • [30] Disitamab vedotin and zimberelimab combined with stereotactic body radiation therapy for the treatment of recurrent, metastatic cervical cancer: A single-arm, open-label, phase II study
    Xu, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S592 - S593
12345